Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia
josé vazquez
Antimicrobial Agents and Chemotherapy, 2004
View PDFchevron_right
Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial
Mohlim Ong
BMC Infectious Diseases, 2013
View PDFchevron_right
Predictors for Prolonged Hospital Stay Solely to Complete Intravenous Antifungal Treatment in Patients with Candidemia: Results from the ECMM Candida III Multinational European Observational Cohort Study
Alida Talento
Mycopathologia, 2023
View PDFchevron_right
Treatment of Severe Candida Infections in High-Risk Patients in Germany: Consensus Formed by a Panel of Interdisciplinary Investigators
Arno Schmalreck
European Journal of Clinical Microbiology & Infectious Diseases, 2002
View PDFchevron_right
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis
E. Raise
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016
View PDFchevron_right
Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies
J. Fortún
Open Forum Infectious Diseases, 2021
View PDFchevron_right
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
Elias Anaissie
Clinical Infectious Diseases, 2009
View PDFchevron_right
Timing for Step-Down Therapy of Candidemia in Non-Neutropenic Patients: An International Multi-Center Study
Thais Guimaraes
Mediterranean Journal of Hematology and Infectious Diseases, 2021
View PDFchevron_right
Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study
Katie Suda
Clinical Infectious Diseases, 2006
View PDFchevron_right
Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
J. Martinez-Montauti
Clinical Microbiology and Infection, 2016
View PDFchevron_right
Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia
G. Raponi
Journal of Chemotherapy, 2010
View PDFchevron_right
Current Treatment Strategies for Disseminated Candidiasis
Scott Filler
Clinical Infectious Diseases, 2006
View PDFchevron_right
Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care
Yoshio Takesue
Journal of Infection and Chemotherapy, 2012
View PDFchevron_right
Fluconazole therapy for treatment of invasive candidiasis in Intensive Care patients. Is it still valid from a pharmacological point of view
Paolo Mura
2014
View PDFchevron_right
Directed antifungal treatment In patients with candidemia: Factors that influence drug selection
David campany herrero
2018
View PDFchevron_right
Early treatment of candidemia in adults: a review
Susan McCormick Hadley
Medical Mycology, 2011
View PDFchevron_right
Breakthrough candidaemia in the era of broad-spectrum antifungal therapies
mora obed
Clinical Microbiology and Infection, 2016
View PDFchevron_right
Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre(R) YeastOne(R) for Candida albicans: a prospective observational cohort study
Tania Sorrell
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study
Thomas Bregenzer
The Journal of infection, 2018
View PDFchevron_right
Preventing candidain high-risk patients
Gervais Chapuis
Critical Care, 1999
View PDFchevron_right
Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia
Lai-Chu See
Journal of Microbiology, Immunology and Infection, 2014
View PDFchevron_right
European expert opinion on the management of invasive candidiasis in adults
Murat Akova
Clinical Microbiology and Infection, 2011
View PDFchevron_right
Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial
Ploenchan Chetchotisakd
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018
View PDFchevron_right
A Randomized and Blinded Multicenter Trial of High‐Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects
Jeannette Lee
Clinical Infectious Diseases, 2003
View PDFchevron_right
Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. results from a six-year study (1996–2001)
Mateu Espasa
Diagnostic Microbiology and Infectious Disease, 2003
View PDFchevron_right